Eli Lilly’s revenue estimates
Analysts estimate an increase of ~6.4% in Eli Lilly’s (LLY) 3Q17 revenues to $5.9 billion following the strong performance of some of the company’s existing products as well as new products in 3Q17.
The above graph shows the revenues of Eli Lilly (LLY) in each quarter and estimates for 3Q17. The company has its operations in over 120 countries, and nearly 45% of total revenues come from sales outside the US markets.
Segment-wise expectations for 3Q17
Lilly’s business is divided into two segments:
- human pharmaceuticals under the brand Lilly
- animal health products under the brand Elanco
Eli Lilly has reported growth in revenues over the past few quarters driven by the strong performance of new products as well as some of the existing products. The revenues have been impacted by the lower sales of its blockbuster drug Cymbalta, following the patent expiry of the drug.
The human pharmaceuticals segment is the largest revenue contributor for Eli Lilly with contributions of over 86% of total revenues for the company. Analysts estimate a strong performance from drugs Basaglar, Cyramza, Effient, Forteo, Humulin, Jardiance, Trulicity, and Taltz will drive growth in 3Q17, while a weak performance from Alimta, Cialis, Cymbalta, Humalog, Strattera, and Zyprexa will offset the growth during 3Q17.
Elanco, the animal health business, contributes ~13.5% of total revenues for Lilly. Analysts estimate the revenues will fall in 3Q17 as compared to 3Q16. The decline in revenues is mainly due to lower sales of food and other products in the US markets as well as international markets. The decline will be partially offset by the strong sales of companion animal products in the US markets during 3Q17.
The iShares Core S&P 500 ETF (IVV) holds 0.4% of its total assets in Eli Lilly and Co. (LLY). IVV also holds 0.4% in Abbott Laboratories (ABT), 0.5% in Bristol-Myers Squibb (BMY), and 0.5% in Celgene (CELG).